COX2-Binding Diagnostic Composition for Blood-Brain Barrier Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for diseases associated with COX2 overexpression, particularly those affecting the brain, lack the ability to quickly and accurately detect the protein's expression levels due to poor permeability through the blood-brain barrier.
Innovation Solution
A diagnostic composition comprising a compound that interacts with specific amino acids (N181, T564, S567, and S565) of the COX2 protein, allowing for direct binding and accurate detection of COX2 overexpression, including neurodegenerative diseases, by forming hydrogen bonds or nucleophilic acyl substitution reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods are used, then the diagnosis can be performed, but the detection speed and accuracy are insufficient due to poor permeability through the blood-brain barrier
Solution Approach 1:
The patent modifies the chemical structure of diagnostic compounds by introducing specific functional groups (hydroxyl, carboxyl, amino, or carbonyl groups) at predetermined positions to enhance binding affinity to COX2 protein. This structural parameter change enables the compound to overcome the blood-brain barrier permeability issue while maintaining high detection accuracy for COX2 overexpression in neurodegenerative diseases
Solution Approach 2:
The patent uses COX2 protein as an intermediary target. By designing compounds that specifically bind to COX2 through hydrogen bonds or nucleophilic acyl substitution reactions, the diagnostic agent indirectly detects the protein's presence and expression level in the brain, overcoming the difficulty of directly measuring COX2 through the blood-brain barrier
2Measurement precision
If the compound binds strongly to COX2 protein, then the detection accuracy improves, but the compound may interfere with normal COX2 function
Solution Approach 1:
The patent introduces functional groups at specific local positions (N181, T564, S567, or S565) of the COX2 protein binding site. This localized modification enables strong binding for detection while the rest of the compound structure maintains biocompatibility, minimizing interference with normal COX2 enzymatic function
Solution Approach 2:
The patent designs diagnostic compounds that bind transiently to COX2 for detection purposes, similar to antibody-antigen interactions. The compound serves its diagnostic function and then dissociates, avoiding prolonged interference with COX2 function while maintaining high detection accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound enables rapid and precise diagnosis of COX2-related diseases by enhancing binding affinity to the COX2 protein, potentially identifying early stages of neurodegenerative disorders through techniques like PET, SPECT, or MRI.
Implementation Method 1
forming hydrogen bonds or nucleophilic acyl substitution reactions
Implementation Method 2
forming hydrogen bonds or nucleophilic acyl substitution reactions
Data Source
AI summary
The present invention relates to a composition for diagnosing diseases associated with cyclooxygenase 2 (COX2) overexpression and a screening method therefor and, more particularly, to: a composition for diagnosing diseases associated with COX2 overexpression, containing a compound with a structural feature of exhibiting strong binding activity to a COX2 protein; and a screening method therefor.